Brief: Overland ADCT Biopharma Announces NMPA Accepts Biologics License Application And Grants Priority Review For Zynlonta® For Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
24/07/2023 12:42
July 24 (Reuters) - ADC Therapeutics SA ADCT.N :
* OVERLAND ADCT BIOPHARMA ANNOUNCES NMPA ACCEPTS BIOLOGICS
LICENSE
APPLICATION AND GRANTS PRIORITY REVIEW FOR ZYNLONTA® FOR
TREATMENT OF RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL
LYMPHOMA
Source text for Eikon: ID:nGNXb4nNT5
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview